Work

Genetically informed therapy for valvular heart disease: what, where, and when to target

Year: 2026

Type: article

Abstract: Treatment of valvular heart disease (VHD) has advanced substantially through surgical and transcatheter valve repair and replacement. However, effective pharmacological therapies that directly modify valve pathobiology remain lacking for most forms of VHD.1 In this issue of eBioMedicine, Moura-Ferreira et al.2 bring genetics and therapeutics together by linking VHD-associated variation to target tractability, existing drugs, and clinical and experimental evidence. Among 431 candidate genes with available tractability information, only 51 were linked to existing compounds, corresponding to 388 pharmacological agents.

Source: EBioMedicine

DOI: 10.1016/j.ebiom.2026.106529

Authors: Yuze Mi, Yanggang Hong

Institutions: Wenzhou Medical University, Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University

Language: English

Topic: Cardiac Valve Diseases and Treatments

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,780